Influence of apolipoprotein e ε4 on rates of cognitive and functional decline in mild cognitive impairment

Danielle C. Whitehair, Abdullah Sherzai, Jennifer Emond, Rema Raman, Paul S. Aisen, Ronald Carl Petersen, Adam S. Fleisher

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background: Apolipoprotein E ε4 (APOE ε4) allele carrier status has been well established as a risk factor for developing Alzheimer's disease. However, the specific influence of APOE ε4 allele status on cognitive and functional rates of decline in mild cognitive impairment (MCI) is poorly understood. We examine the prospective association of APOE ε4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI). Methods: A total of 516 aMCI participants aged 55-90 years who received placebo or vitamin E from the Alzheimer's Disease Cooperative Study's MCI treatment trial were evaluated. During the 36-month study period, neurocognitive and functional measures were collected. These measures were assessed over time for change and association with APOE ε4 status. Generalized Estimating Equations were performed to model each outcome measure over the study period. Results: APOE ε4 status had a significant impact on cognitive and functional decline on multiple measures; those who were APOE ε4 positive had significantly more rapid decline in performance on all cognitive and functional measures except Number Cancellation and Maze tracing (P < .05). The greatest decline was seen in global measures of cognition and function including the Clinical Diagnostic Rating scale, followed by the Mini-Mental State Examination, Global Deterioration scale, and the Alzheimer's Disease Assessment Scale-Cognitive Subscale. Conclusions: These findings demonstrate that APOE ε4 genotype is predictive of increased general rates of decline with global measures of cognition and function most affected. With accelerated declines in common clinical trial primary efficacy measures, APOE ε4 status needs to be accounted for in treatment trials of MCI.

Original languageEnglish (US)
Pages (from-to)412-419
Number of pages8
JournalAlzheimer's and Dementia
Volume6
Issue number5
DOIs
StatePublished - Sep 2010

Fingerprint

Apolipoprotein E4
Apolipoproteins
Alzheimer Disease
Alleles
Cognition
Cognitive Dysfunction
Vitamin E
Genotype
Placebos
Outcome Assessment (Health Care)
Clinical Trials

Keywords

  • All cognitive disorders/dementia
  • All genetics
  • Alzheimer's disease
  • MCI (mild cognitive impairment)
  • Risk factors in epidemiology

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Influence of apolipoprotein e ε4 on rates of cognitive and functional decline in mild cognitive impairment. / Whitehair, Danielle C.; Sherzai, Abdullah; Emond, Jennifer; Raman, Rema; Aisen, Paul S.; Petersen, Ronald Carl; Fleisher, Adam S.

In: Alzheimer's and Dementia, Vol. 6, No. 5, 09.2010, p. 412-419.

Research output: Contribution to journalArticle

Whitehair, Danielle C. ; Sherzai, Abdullah ; Emond, Jennifer ; Raman, Rema ; Aisen, Paul S. ; Petersen, Ronald Carl ; Fleisher, Adam S. / Influence of apolipoprotein e ε4 on rates of cognitive and functional decline in mild cognitive impairment. In: Alzheimer's and Dementia. 2010 ; Vol. 6, No. 5. pp. 412-419.
@article{c219da3a0463406b92adbe1b726d52e7,
title = "Influence of apolipoprotein e ε4 on rates of cognitive and functional decline in mild cognitive impairment",
abstract = "Background: Apolipoprotein E ε4 (APOE ε4) allele carrier status has been well established as a risk factor for developing Alzheimer's disease. However, the specific influence of APOE ε4 allele status on cognitive and functional rates of decline in mild cognitive impairment (MCI) is poorly understood. We examine the prospective association of APOE ε4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI). Methods: A total of 516 aMCI participants aged 55-90 years who received placebo or vitamin E from the Alzheimer's Disease Cooperative Study's MCI treatment trial were evaluated. During the 36-month study period, neurocognitive and functional measures were collected. These measures were assessed over time for change and association with APOE ε4 status. Generalized Estimating Equations were performed to model each outcome measure over the study period. Results: APOE ε4 status had a significant impact on cognitive and functional decline on multiple measures; those who were APOE ε4 positive had significantly more rapid decline in performance on all cognitive and functional measures except Number Cancellation and Maze tracing (P < .05). The greatest decline was seen in global measures of cognition and function including the Clinical Diagnostic Rating scale, followed by the Mini-Mental State Examination, Global Deterioration scale, and the Alzheimer's Disease Assessment Scale-Cognitive Subscale. Conclusions: These findings demonstrate that APOE ε4 genotype is predictive of increased general rates of decline with global measures of cognition and function most affected. With accelerated declines in common clinical trial primary efficacy measures, APOE ε4 status needs to be accounted for in treatment trials of MCI.",
keywords = "All cognitive disorders/dementia, All genetics, Alzheimer's disease, MCI (mild cognitive impairment), Risk factors in epidemiology",
author = "Whitehair, {Danielle C.} and Abdullah Sherzai and Jennifer Emond and Rema Raman and Aisen, {Paul S.} and Petersen, {Ronald Carl} and Fleisher, {Adam S.}",
year = "2010",
month = "9",
doi = "10.1016/j.jalz.2009.12.003",
language = "English (US)",
volume = "6",
pages = "412--419",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Influence of apolipoprotein e ε4 on rates of cognitive and functional decline in mild cognitive impairment

AU - Whitehair, Danielle C.

AU - Sherzai, Abdullah

AU - Emond, Jennifer

AU - Raman, Rema

AU - Aisen, Paul S.

AU - Petersen, Ronald Carl

AU - Fleisher, Adam S.

PY - 2010/9

Y1 - 2010/9

N2 - Background: Apolipoprotein E ε4 (APOE ε4) allele carrier status has been well established as a risk factor for developing Alzheimer's disease. However, the specific influence of APOE ε4 allele status on cognitive and functional rates of decline in mild cognitive impairment (MCI) is poorly understood. We examine the prospective association of APOE ε4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI). Methods: A total of 516 aMCI participants aged 55-90 years who received placebo or vitamin E from the Alzheimer's Disease Cooperative Study's MCI treatment trial were evaluated. During the 36-month study period, neurocognitive and functional measures were collected. These measures were assessed over time for change and association with APOE ε4 status. Generalized Estimating Equations were performed to model each outcome measure over the study period. Results: APOE ε4 status had a significant impact on cognitive and functional decline on multiple measures; those who were APOE ε4 positive had significantly more rapid decline in performance on all cognitive and functional measures except Number Cancellation and Maze tracing (P < .05). The greatest decline was seen in global measures of cognition and function including the Clinical Diagnostic Rating scale, followed by the Mini-Mental State Examination, Global Deterioration scale, and the Alzheimer's Disease Assessment Scale-Cognitive Subscale. Conclusions: These findings demonstrate that APOE ε4 genotype is predictive of increased general rates of decline with global measures of cognition and function most affected. With accelerated declines in common clinical trial primary efficacy measures, APOE ε4 status needs to be accounted for in treatment trials of MCI.

AB - Background: Apolipoprotein E ε4 (APOE ε4) allele carrier status has been well established as a risk factor for developing Alzheimer's disease. However, the specific influence of APOE ε4 allele status on cognitive and functional rates of decline in mild cognitive impairment (MCI) is poorly understood. We examine the prospective association of APOE ε4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI). Methods: A total of 516 aMCI participants aged 55-90 years who received placebo or vitamin E from the Alzheimer's Disease Cooperative Study's MCI treatment trial were evaluated. During the 36-month study period, neurocognitive and functional measures were collected. These measures were assessed over time for change and association with APOE ε4 status. Generalized Estimating Equations were performed to model each outcome measure over the study period. Results: APOE ε4 status had a significant impact on cognitive and functional decline on multiple measures; those who were APOE ε4 positive had significantly more rapid decline in performance on all cognitive and functional measures except Number Cancellation and Maze tracing (P < .05). The greatest decline was seen in global measures of cognition and function including the Clinical Diagnostic Rating scale, followed by the Mini-Mental State Examination, Global Deterioration scale, and the Alzheimer's Disease Assessment Scale-Cognitive Subscale. Conclusions: These findings demonstrate that APOE ε4 genotype is predictive of increased general rates of decline with global measures of cognition and function most affected. With accelerated declines in common clinical trial primary efficacy measures, APOE ε4 status needs to be accounted for in treatment trials of MCI.

KW - All cognitive disorders/dementia

KW - All genetics

KW - Alzheimer's disease

KW - MCI (mild cognitive impairment)

KW - Risk factors in epidemiology

UR - http://www.scopus.com/inward/record.url?scp=77956372189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956372189&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2009.12.003

DO - 10.1016/j.jalz.2009.12.003

M3 - Article

C2 - 20813342

AN - SCOPUS:77956372189

VL - 6

SP - 412

EP - 419

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 5

ER -